Person: DOĞAN, ELİF ECE
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Organizational Unit
Job Title
Last Name
DOĞAN
First Name
ELİF ECE
Name
11 results
Search Results
Now showing 1 - 10 of 11
- PublicationMetadata onlyManagement of Rabson-Mendenhall syndrome(2013-09-22) ÖZGEN, İLKER TOLGA; CESUR, YAŞAR; DEMİRKOL, DEMET; GEDİK, AHMET HAKAN; AKSU, MEHMET ŞİRİN; ÖZGEN, İLKER TOLGA; CESUR, YAŞAR; VEHAPOĞLU TÜRKMEN, AYSEL; DOĞAN, ELİF ECE; DOĞAN DEMİR, AYŞEGÜL
- PublicationMetadata onlyHyperbaric oxygen therapy of olfactory dysfunction in diabetic neuropathy with type 2 diabetes mellitus and a new definition -diabetic olfactopathy-(2016-01-01) Dogan, ELİF ECE; Veyseller, Bayram; DOĞAN, REMZİ; AKSOY, Fadlullah; ÖZTURAN, ORHAN; TUGRUL, Selahattin; YENİGÜN, ALPER; DOĞAN, REMZI; YENİGÜN, ALPER; AKSOY, FADLULLAH; DOĞAN, ELİF ECE; ÖZTURAN, ORHAN
- PublicationMetadata onlyEFFECTS OF FASTING ON RENAL FUNCTION OF PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE(2016-05-01T00:00:00Z) Ekinci, Iskender; KAZANCIOĞLU, Rümeyza; Erkoc, Reha; Kili, Elif; DOĞAN, ELİF ECE; GÜRSU, Meltem; Cebeci, Egemen; Ozturk, Savas; KAZANCIOĞLU, RÜMEYZA; DOĞAN, ELİF ECE; GÜRSU, MELTEM
- PublicationMetadata onlySisplatin nefrotoksisitesinin önlenmesi ve tedavisinde proxeed plus’ın etkisi: deneysel rat çalışması.(2017-12-22) DOĞAN, ELİF ECE; KAZANCIOĞLU, RÜMEYZA; DOĞAN, ELİF ECE; KAZANCIOĞLU, RÜMEYZA
- PublicationMetadata onlyEffects of fasting during the month of Ramadan on renal function in patients with autosomal dominant polycystic kidney disease .(2018-02-01) EKINCI, I; ERKOC, R; GURSU, MELTEM; DOGAN, ELİF ECE; KILIC, ERDEM; CEBECI, E; OZTURK, S; Kazancioglu, RÜMEYZA; GÜRSU, MELTEM; DOĞAN, ELİF ECE; KILIÇ, ERDEM; KAZANCIOĞLU, RÜMEYZA
- PublicationMetadata onlyPROTECTIVE EFFECT OF DEXPANTHENOL AGAINST NEPHROTOXIC EFFECT OF AMIKACIN: AN EXPERIMENTAL STUDY(2015-05-01) Dogan, Elif Ece; Erkoc, Reha; Ekinci, Iskender; Hamdard, Jamshid; KARATOPRAK, CUMALİ; Cikrikcioglu, Mehmet Ali; ÇOBAN, GANİME; ÖZER, ÖMER FARUK; KAZANCIOĞLU, RÜMEYZA; DOĞAN, ELİF ECE; KARATOPRAK, CUMALİ; ÇOBAN, GANİME; ÖZER, ÖMER FARUK; KAZANCIOĞLU, RÜMEYZA
- PublicationMetadata onlyProtective effect of dexpanthenol against nephrotoxic effect of amikacin: An experimental study(2017-05-01) Dogan, ELİF ECE; ERKOC, Reha; EKINCI, Iskender; HAMDARD, Jamshid; DONER, Baris; KARATOPRAK, CUMALİ; Coban, GANİME; Ozer, Omer Faruk; Kazancioglu, RÜMEYZA; DOĞAN, ELİF ECE; KARATOPRAK, CUMALİ; ÇOBAN, GANİME; ÖZER, ÖMER FARUK; KAZANCIOĞLU, RÜMEYZABackground: Amikacin has the largest spectrum among aminoglycosides, its nephrotoxic effect limits its utilization. Our purpose in this study is to review the protective effect of dexpanthenol against the nephrotoxic effect of amikacin, accompanied with histopathological and biochemical parameters.
- PublicationMetadata onlyPatients treated with therapeutic plasma exchange: A single center experience(2014-12-01) SAMANCI, Nilay Sengul; AYER, Mesut; Gursu, MELTEM; Ar, Muhlis Cem; YEL, Kubra; ERGEN, Abdulkadir; Dogan, ELİF ECE; KARADAG, Serhat; CEBECI, Egemen; TOPTAS, Mehmet; Kazancioglu, RÜMEYZA; OZTURK, Savas; GÜRSU, MELTEM; DOĞAN, ELİF ECE; KAZANCIOĞLU, RÜMEYZAIntroduction: Therapeutic Plasma Exchange (TPE) is a therapeutic procedure that is used to remove high molecular weight substances from plasma. We analyzed data of patients who received TPE during the last 7 years, and focused on the efficiency of TPE in various disease groups.
- PublicationOpen AccessCD40 ligand and P-selectin in heterozygous Beta-thalassemia(2016-06-01) CIKRIKCIOGLU, Mehmet Ali; SOYTAS, Rabia Bag; KILIC, Elif; Toprak, Aybala Erek; Karatoprak, CUMALİ; Zorlu, MEHMET; Kiskac, MUHARREM; EMEGIL, Sebnem; Cetin, GÜVEN; Dogan, ELİF ECE; SEKIN, Yahya; HAMDARD, Jamshid; ÇAKIRCA, MUSTAFA; ZORLU, MEHMET; KISKAÇ, MUHARREM; ÇETİN, GÜVEN; DOĞAN, ELİF ECE; KARATOPRAK, CUMALİObjective: To investigate platelet functions and measure soluble CD40 ligand, soluble P-selectin, beta-thromboglobulin and platelet factor 4 levels in the blood of heterozygous beta thalassemia patients. Methods: The cross-sectional case-control study was conducted at Bezmialem Vakif University, Istanbul, Turkey, between September 2013 and April 2014, and comprised heterozygous beta thalassemia patients who were compared with 41 gender-, age- and body mass index-matched controls for platelet function markers. The two groups were also compared for co-morbidities, smoking, and regular medications. Results: Of the 78(78.78) subjects, 50(64%) were women and 28(36%) men with an overall mean age of 39.4±12.7 years (range: 18-79 years). The mean body mass index was 26.3±4.2. The heterozygous beta thalassemia group included 37(47%) subjects [24(65%) females; 13(35%) males] while the control group had 41(53%) [26(63%) females; 15(37%) males]. Soluble CD40 ligand and soluble P-selectin were lower in the heterozygous beta thalassemia group (p=0.009; p=0.010). Beta-thromboglobulin and platelet factor 4 levels were comparable between the groups (p=0.497; p=0.507.). Conclusions: Some platelet functions may be reduced in heterozygous beta thalassemia patients, which may be related to their lower incidence of cerebral and cardiac ischaemic events.
- PublicationMetadata onlyEFFECTS OF PROXEED PLUS IN THE PREVENTION AND TREATMENT OF CISPLATIN NEPHROTOXICITY: AN EXPERIMENTAL RAT STUDY(2018-05-01) Dogan, ELİF ECE; Aydin, Mehmet Serif; Guler, ERAY METİN; Kocyigit, ABDÜRRAHİM; Gursu, MELTEM; Seker, MESUT; Kazancioglu, RÜMEYZA; DOĞAN, ELİF ECE; GÜLER, ERAY METİN; KOÇYİĞİT, ABDÜRRAHİM; GÜRSU, MELTEM; ŞEKER, MESUT; KAZANCIOĞLU, RÜMEYZA